Pulse Biosciences

PLSE · NASDAQ

$50.84+$3.29 (+6.92%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $47.55

Latest news

Press releaseOct 14, 7:00 AM ETBusiness Wire
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Press releaseOct 9, 4:05 PM ETBusiness Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 8, 7:00 AM ETBusiness Wire
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Press releaseOct 7, 7:00 AM ETBusiness Wire
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Press releaseSep 15, 7:00 AM ETBusiness Wire
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
NewsSep 10, 10:02 AM ETAvi Kapoor
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
NewsSep 9, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseSep 4, 7:00 AM ETBusiness Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 18, 7:00 AM ETBusiness Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 6, 4:05 PM ETBusiness Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Press releaseJul 30, 4:05 PM ETBusiness Wire
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
NewsJul 29, 7:03 AM ET
Pulse Biosciences Says NANOPULSE-AF Atrial Fibrillation Study Surpasses Enrollment Midpoint After April 2026 Start; Update Due On August 6 Earnings Call
Press releaseJul 29, 7:00 AM ETBusiness Wire
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Press releaseJul 21, 4:05 PM ETBusiness Wire
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Press releaseJul 15, 4:05 PM ETBusiness Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsJun 26, 10:18 AM ETAvi Kapoor
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Press releaseJun 10, 7:00 AM ETBusiness Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Press releaseMay 27, 4:05 PM ETBusiness Wire
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Press releaseMay 12, 7:00 AM ETBusiness Wire
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Press releaseMay 8, 7:00 AM ETBusiness Wire
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
Press releaseMay 4, 7:00 AM ETBusiness Wire
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Press releaseApr 25, 1:00 PM ETBusiness Wire
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Press releaseApr 20, 7:00 AM ETBusiness Wire
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Press releaseApr 17, 7:00 AM ETBusiness Wire
Pulse Biosciences to Host Analyst Event on April 25, 2026
Press releaseApr 9, 7:00 AM ETBusiness Wire
Pulse Biosciences Strengthens Executive Leadership Team
Press releaseApr 7, 7:00 AM ETBusiness Wire
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Press releaseApr 2, 4:05 PM ETBusiness Wire
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
NewsMar 17, 7:03 AM ET
Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib).
Press releaseMar 17, 7:00 AM ETBusiness Wire
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Press releaseMar 12, 7:00 AM ETBusiness Wire
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
NewsFeb 19, 4:08 PM ET
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
Press releaseFeb 19, 4:05 PM ETBusiness Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
NewsFeb 18, 2:01 PM ET
A Glimpse of Pulse Biosciences's Earnings Potential
NewsFeb 9, 9:18 AM ETVandana Singh
What's Going With Pulse Biosciences Stock On Monday?
NewsFeb 6, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseJan 9, 7:00 AM ETBusiness Wire
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Press releaseDec 9, 7:00 AM ETBusiness Wire
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
Press releaseNov 5, 4:05 PM ETBusiness Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsAug 13, 11:44 AM ETAvi Kapoor
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday

12 Health Care Stocks Moving In Wednesday's Intraday Session

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences Says NANOPULSE-AF Atrial Fibrillation Study Surpasses Enrollment Midpoint After April 2026 Start; Update Due On August 6 Earnings Call

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Earnings Scheduled For May 4, 2026

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Pulse Biosciences to Host Analyst Event on April 25, 2026

Pulse Biosciences Strengthens Executive Leadership Team

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib).

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences Q4 Earnings Report: What Investors Need to Know

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

A Glimpse of Pulse Biosciences's Earnings Potential

What's Going With Pulse Biosciences Stock On Monday?

12 Health Care Stocks Moving In Friday's Intraday Session

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Earnings Scheduled For May 8, 2025

Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday